CAM
OBIO icon

Cormorant Asset Management’s Orchestra BioMed OBIO Stock Holding History

Cormorant Asset Management’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-240,000
Closed -$2.45M – 97
2021
Q2 		$2.45M Sell
240,000
-560,000
-70% -$5.79M 0.08% 91
2021
Q1 		$8.98M Hold
800,000
– – 0.2% 75
2020
Q4 		$10.2M Hold
800,000
– – 0.24% 63
2020
Q3 		$8.8M Buy
+800,000
New +$8.98M 0.34% 62

Other funds holding OBIO

DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AC
Amitell Capital Singapore $109M AUM 50.64% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Cormorant Asset Management's OBIO Position: Q3 2021 in Review

Cormorant Asset Management sold out of Orchestra BioMed (OBIO) in Q3 2021, closing a stake of 240,000 shares — an estimated $2.45M sold.

Cormorant Asset Management first reported a position in OBIO in Q3 2020 and held it in 4 quarters. The position peaked at $10.2M in Q4 2020. 48 funds tracked by Wall St. Rank hold OBIO as of Q3 2021.

  • Cormorant Asset Management reported no remaining Orchestra BioMed position as of Q3 2021 after selling out during the quarter.
  • Cormorant Asset Management sold 240,000 Orchestra BioMed shares in Q3 2021, an estimated $2.45M.
  • Cormorant Asset Management first reported a position in Orchestra BioMed in Q3 2020 and held it in 4 quarters.
  • Cormorant Asset Management's Orchestra BioMed position peaked at $10.2M in Q4 2020.
  • 48 funds tracked by Wall St. Rank held Orchestra BioMed as of Q3 2021.

Based on Cormorant Asset Management's 13F filing for Q3 2021, filed 15 Nov 2021.